CATALYSIS Advises Point-of-Care Diagnostic Developer Åmic AB in SEK 102 Million Financing

CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Åmic AB in a Preferred Series C financing raising SEK 102 million. The investors included funds advised by Investor Growth Capital AB, Innovations Kapital AB and Johnson & Johnson Development Corporation.

Åmic AB (Uppsala, Sweden) is a privately held POC diagnostic company with R&D and manufacturing facilities based in Uppsala, Sweden. The company is developing the next generation of POC diagnostic tests using its proprietary microfluidic technology. The technology uses a moulded plastic device called the 4castchip®, and a state-of-the-art optical detection system for precise and sensitive quantification of immunoassays. The Company intends to launch the Forecast POC Diagnostic System with high-performance test kits for the cardiac markers NT-proBNP and cTnI. The marker specific test cartridge contains the 4castchip® in a user friendly format for rapid analysis of whole-blood patient samples at the point of care. The Forecast Reader is a low-cost analyser designed for fail-safe operation in hospital and primary care settings with full connectivity to laboratory information systems. For more information, visit

CATALYSIS Advises Life Science Innovators.  Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.